These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34778040)

  • 61. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Should Baseline Hemoglobin A
    Uhrig JL; Page SO; Mishriky BM; Patil SP; Powell JR; Sewell K; Mian MR; Cummings DM
    J Clin Pharmacol; 2020 Aug; 60(8):980-991. PubMed ID: 32396236
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
    J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
    Suissa S
    Diabetes Care; 2018 Jan; 41(1):6-10. PubMed ID: 29263192
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
    Okada S; Okada K; Okada J; Kikkawa K; Yamada E; Saito T; Andou T; Ohshima K
    Diabetes Metab Syndr; 2023 Jul; 17(7):102806. PubMed ID: 37343509
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus.
    Choi Y; Ko SH; Chang K; Yoo KD; Ihm SH
    J Diabetes; 2023 Nov; 15(11):944-954. PubMed ID: 37528628
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
    Franchi M; Pellegrini G; Avogaro A; Buzzetti G; Candido R; Cavaliere A; Consoli A; Marzona I; Mennini FS; Palcic S; Corrao G
    BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38802266
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2.
    Hastrup S; Hedegaard JN; Andersen G; Rungby J; Johnsen SP
    Eur J Neurol; 2024 Aug; 31(8):e16329. PubMed ID: 38715389
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.
    Al-Mashhadi ZK; Viggers R; Fuglsang-Nielsen R; Vestergaard P; Gregersen S; Starup-Linde J
    Front Endocrinol (Lausanne); 2022; 13():882998. PubMed ID: 36299454
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
    Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
    Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
    Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan.
    Chen KC; Chung CH; Lu CH; Tzeng NS; Lee CH; Su SC; Kuo FC; Liu JS; Hsieh CH; Chien WC
    J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121372
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
    Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
    Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
    [No Abstract]   [Full Text] [Related]  

  • 79. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
    Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
    J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
    Morieri ML; Consoli A; Sesti G; Purrello F; Avogaro A; Fadini GP;
    Diabetes Metab Res Rev; 2021 Jan; 37(1):e3353. PubMed ID: 32453482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.